Table 1 Estimated target population
| Â | Â | % | Reference | N |
|---|---|---|---|---|
1 | Patients with lung cancer in 2020 | (18) | 28,475 | |
2 | Patients with NSCLC | 85.0% | (3) | 24,204 |
3 | Stage VI in samples of NSCLC patients | 54.5% | (19) | 13,191 |
4 | Patients with stage IV NSCLC non-squamous subtype | 66.9% | (20) | 8825 |
5 | Patients with stage IV NSCLC squamous subtype | 33.1% | (20) | 4366 |
6 | Patients with stage IV NSCLC squamous subtype, never smokers | 16.0% | (21) | 699 |
7 | Candidate for ALK rearrangement diagnosis (steps 4 + 6) | 9523 | ||
8 | Patients finally tested for ALK (testing rate) | 80.1% | (22) | 7628 |